Navigation Links
Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
Date:5/6/2008

89,105

Total liabilities and shareholders' equity $97,118 $105,140

This release contains forward-looking statements, including statements regarding the Company's financial condition and results of operations, business objectives and strategic goals, drug development plans, timing and results of clinical trials and the potential safety and efficacy of its products in development. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the Company's research and development activities; the results of pre-clinical and clinical testing; the receipt and timing of required regulatory approvals; the market's acceptance of the Company's proposed products; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; competition from third parties; the Company's ability to preserve and protect intellectual property rights; the Company's dependence on third-party manufacturers and suppliers; the Company's lack of sales and marketing experience; the Company's ability to attract and retain key personnel; changes in technology, government regulation and general market conditions; and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K for the year ended December 31, 2007 and its Quarterly Report on Form 10-Q for the period ended March 31, 2008, which will be filed with the SEC on or about May 8, 2008. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipat
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Poniard Pharmaceuticals Announces Upcoming Conference Participation
2. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
5. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
6. Onyx Pharmaceuticals Reports 2008 First Quarter Results
7. SGX Pharmaceuticals Schedules Teleconference and Webcast to Discuss First Quarter 2008 Results and Provide Pipeline Update
8. Israels Prestigious Presidents Conference to Feature Oramed Pharmaceuticals Revolutionary Oral Insulin Capsule
9. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
10. Keryx Biopharmaceuticals to Present at the Deutsche Bank 33rd Annual Health Care Conference
11. GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... (PRWEB) February 27, 2015 Immunovaccine ... and immunotherapy company, today announced that the U.S. ... for Fast Track designation and Phase I clinical ... conjunction with the mutual co-development agreement signed with ... Fast Track designation for the DPX-Survivac. , “We ...
(Date:2/27/2015)... ADELAIDE, Australia , Feb. 27, 2015 ... data from the DisrupTOR-1 trial of BNC105 in patients ... Symposium in Orlando, Florida . The ... of the City of Hope Comprehensive Cancer Center ... presentation. The new data identifies Ferritin ...
(Date:2/27/2015)... Brighton, Illinois (PRWEB) February 27, 2015 ... Matt Sims, General Manager of State Line Farms, received ... Award recognizes a producer, under the age of 35, ... , "It is an honor to win the Tomorrow's ... to discovering who won the Top Producer Award and ...
(Date:2/27/2015)... -- Steep Hill, the industry leader in cannabis testing and ... a full service medical cannabis quality assurance laboratory in ... scientific tools and methodology to the state, for regulatory ... the only laboratory licensed by the New Mexico Department ... order to meet the recently adopted regulatory requirements pertaining ...
Breaking Biology Technology:Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 2
... March 31 DOR BioPharma, Inc. (OTC Bulletin Board: ... today announced its financial results for 2008. DOR,s revenues ... million in 2007. The increase was due primarily ... the resulting achievement of certain research and development milestones ...
... IDM Pharma, Inc. (Nasdaq: IDMI ) today ... ended December 31, 2008. Financial information presented represents the ... Pharma S.A.Total revenues in the quarter ended December 31, 2008 ... $0.07 per share for the quarter. Total revenues for ...
... leader of cell line manufacturing, Selexis is now ... recombinant protein drugs with added characterization servicesGENEVA, March ... offering technologies and services for the rapid development ... an expanded offering focusing on the biosimilar market ...
Cached Biology Technology:DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments 2DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments 3DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments 4DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments 5IDM Pharma Reports 2008 Financial Results 2IDM Pharma Reports 2008 Financial Results 3IDM Pharma Reports 2008 Financial Results 4IDM Pharma Reports 2008 Financial Results 5IDM Pharma Reports 2008 Financial Results 6IDM Pharma Reports 2008 Financial Results 7IDM Pharma Reports 2008 Financial Results 8Selexis Launches Biosimilar Cell Line Development Program 2
(Date:1/22/2015)...  BellBrook Labs, a leader in high throughput screening ... a TR-FRET (time resolved Forster resonance energy transfer) ... high throughput screening assay for glycosyltransferases and other ... sensitive detection of hundreds of human and microbial ...
(Date:1/22/2015)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) a biometric authentication ... success of the Wocket™ smart wallet at CES 2015 in ... as one of the "11 Hot Products at CES" in a review ... So Far" by Newseveryday.com and "The top 10 gadgets from CES 2015" ...
(Date:1/22/2015)... NEW YORK , Jan. 21, 2015  Analyst Report Issued ... Credit Card Brands report showed that planet-wide, transactions at merchants ... 2011, while the total number of credit, debit, and prepaid ... the U.S. were victims of fraudulent card usage in 2012, ...
Breaking Biology News(10 mins):BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... Want to slow the signs of aging and live ... calories could be a promising strategy. Calorie restriction ... rats and mice. While scientists do not know how calorie ... is that it slows aging by decreasing a thyroid hormone, ...
... a bold commitment from Germany, leaders of the world,s ... Summit in Japan to take immediate and substantive action ... pledge of 500 million Euros over four years to ... forest protection, starts to address a major source of ...
... COLLEGE STATION, July 2, 2008 -- Two Texas A&M ... help scientists more accurately study complex units of clustered ... scientists to analyze many bacterial genomes at once, is ... experimentally validated data instead of from statistical predictions, they ...
Cached Biology News:Looking for the Founatain of Youth? Cut your calories, research suggests 2G8 summit: Opportunity for immediate action on climate change 2G8 summit: Opportunity for immediate action on climate change 3Texas A&M researchers develop tool to study complex clusters of genes 2Texas A&M researchers develop tool to study complex clusters of genes 3
... have moderate chemiluminescence efficiencies and the chemistry ... have the added benefit that they require ... the background signal. This benefit has been ... immunoassay applications. These compounds can also be ...
Required to perform reference file generation, flatfield calibration and performance verification processes on the GSD-501...
ssDNA from PCR DNA in less than 1 hour. No gels, columns, or slurries. Sequence from high quality ssDNA: clearer reads, longer runs....
... version of Freezerworks Unlimited includes 2 clients and ... facilitates the sharing of freezers by multiple groups ... Network Client/Server version ... in monitor with 256 colors; OS 8.6 & ...
Biology Products: